Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 23;10(7):e3034.
doi: 10.7759/cureus.3034.

Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review

Syed Ijlal Ahmed  1 , Syeda Beenish Bareeqa  2 , Syeda Sana Samar  3
Affiliations
Review

Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review

Syed Ijlal Ahmed et al. Cureus. .

Abstract

Glioblastoma multiforme (GBM) has been the topic of immense research in recent years. The suitable therapeutic approach towards this wild-type p53 tumor has been the topic of ongoing discussion for some decades now. There has been a substantial debate about the role of mouse double minute-2 (MDM-2) antagonists in the treatment of GBM recently. We have reviewed the current data in our study to establish the consensus about recent interventions. Our review of the literature suggests that MDM-2 antagonists are currently a more suitable approach with improved efficacy, and it might be utilized in the future for significant results. Newer analogs of MDM-2 antagonists with better pharmacokinetics profiles and the least drug-drug interactions were also discussed in our research. It was concluded that MDM-2 antagonists are improved therapy against GBM but evidential proof with more experimental studies is needed to standardize this therapy in near future.

Keywords: glioblastoma (gbm); mdm-2 antagonist; p53 gene.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. Costa B, Bendinelli S, Gabelloni P, et al. PloS One. 2013;2013 - PMC - PubMed
    1. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-Amplified and TP53 wild-type glioblastomas. Verreault M, Schmitt C, Goldwirt L, et al. Clin Cancer Res. 2016:0. - PMC - PubMed
    1. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. Chen X, Tai L, Gao J, et al. J Control Release. 2015;218:29–35. - PMC - PubMed
    1. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, et al. PloS One. 2011 - PMC - PubMed
    1. MDM2 antagonist nutlin‐3a sensitizes tumors to V‐ATPase inhibition. Schneider LS, Ulrich M, Lehr T, Menche D, Müller R, von Schwarzenberg K. Mol Oncol. 2016;10:1054–1062. - PMC - PubMed

LinkOut - more resources